Mobidiag ondertekent meerdere internationale overeenkomsten voor de distributie van haar Amplidiag® en Novodiag® diagnostische oplossingen
Overeenkomsten ondertekend in Griekenland, Letland, Litouwen en Koeweit, met meer in behandeling
ESPOOO, Finland-(BUSINESS WIRE)- Mobidiag Ltd., een commercieel bedrijf voor moleculaire diagnostiek dat zich bezighoudt met de ontwikkeling van antimicrobiële resistentie, kondigt vandaag aan dat het meerdere exclusieve overeenkomsten heeft ondertekend met internationale partners voor de distributie van zijn Amplidiag® en Novodiag® producten in Europa en het Midden-Oosten.
Mobidiag heeft exclusieve overeenkomsten ondertekend voor de distributie van Amplidiag® en Novodiag® met Helix2 voor Griekenland en Interlab INTERAUTOMATIKA UAB voor Letland en Litouwen. Mobidiag heeft ook zijn eerste overeenkomst in het Midden-Oosten ondertekend met Ibn Rushd Medical & Scientific Equipment Co. voor de distributie van Novodiag® in Koeweit. De overeenkomsten zijn onmiddellijk van kracht en gelden aanvankelijk voor een periode van twee jaar.
Mobidiag Signs Multiple International Agreements for Distribution of Its Amplidiag® and Novodiag® Diagnostic Solutions
Agreements signed in Greece, Latvia, Lithuania and Kuwait, with more in discussions
ESPOO, Finland–(BUSINESS WIRE)– Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has signed multiple exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with Helix2 for Greece and Interlab INTERAUTOMATIKA UAB for Latvia and Lithuania. Mobidiag has also signed its first agreement in the Middle East with Ibn Rushd Medical & Scientific Equipment Co. for the distribution of Novodiag® in Kuwait. The agreements are effective immediately and initially in place for a period of two years.
Tuomas Tenkanen, CEO of Mobidiag, said, “We are delighted to have extended our commercial footprint into new international territories including our first agreement in the Middle East. Mobidiag continues to see demand grow for the Amplidiag® and Novodiag® solutions and we are in discussions with several distribution partners in a range of international markets, as customers look for comprehensive diagnostic solutions to a wide range of infectious diseases in both centralised and decentralised laboratories.”
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190224005016/en/
Contacts
Mobidiag
Dorothee Allard, Marketing Communications Manager
+33 1 55 25 17 13
marketing@mobidiag.com
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com